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Abstract
Background: Human genome sequencing has enabled the association of phenotypes with genetic loci, but our
ability to effectively translate this data to the clinic has not kept pace. Over the past 60 years, pharmaceutical
companies have successfully demonstrated the safety and efficacy of over 1,200 novel therapeutic drugs via costly
clinical studies. While this process must continue, better use can be made of the existing valuable data. In silico
tools such as candidate gene prediction systems allow rapid identification of disease genes by identifying the most
probable candidate genes linked to genetic markers of the disease or phenotype under investigation. Integration
of drug-target data with candidate gene prediction systems can identify novel phenotypes which may benefit
from current therapeutics. Such a drug repositioning tool can save valuable time and money spent on preclinical
studies and phase I clinical trials.
Methods: We previously used Gentrepid (http://www.gentrepid.org) as a platform to predict 1,497 candidate genes
for the seven complex diseases considered in the Wellcome Trust Case-Control Consortium genome-wide
association study; namely Type 2 Diabetes, Bipolar Disorder, Crohn’s Disease, Hypertension, Type 1 Diabetes,
Coronary Artery Disease and Rheumatoid Arthritis. Here, we adopted a simple approach to integrate drug data
from three publicly available drug databases: the Therapeutic Target Database, the Pharmacogenomics
Knowledgebase and DrugBank; with candidate gene predictions from Gentrepid at the systems level.
Results: Using the publicly available drug databases as sources of drug-target association data, we identified a
total of 428 candidate genes as novel therapeutic targets for the seven phenotypes of interest, and 2,130 drugs
feasible for repositioning against the predicted novel targets.
Conclusions: By integrating genetic, bioinformatic and drug data, we have demonstrated that currently available
drugs may be repositioned as novel therapeutics for the seven diseases studied here, quickly taking advantage of
prior work in pharmaceutics to translate ground-breaking results in genetics to clinical treatments.
Background
The development of new therapeutics is essential to
improve the human condition and lower the burden of
disease. Due to our limited knowledge of the molecular
basis of complex diseases, comparatively few gene tar-
gets for therapeutics have been identified to date. The
standard approach to developing therapeutics involves
testing many thousands of compounds against a known
target in order to identify a lead compound. The lead
compound can then be further refined in silico and in
vitro before heading into the lengthy and costly clinical
trials pipeline. This process, which consists of phases I,
II, III and IV before final drug approval, involves 10-17
years of drug development, from target identification
until FDA/EMEA approval, with only a 10% probability
of success [1]. As a result, the pharmaceutical industry
spends an average of about 1.2 billion US dollars to
bring each new drug to market [2]. There is also a high
risk associated with de novo drugs due to unforeseen
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adverse side effects, as seen in the case of Thalidomide,
a drug used to treat morning sickness which resulted in
devastating birth defects [3].
A novel approach to therapeutic development is to
identify new applications for drugs that have already
been approved, or have successfully completed phase I
clinical trials which investigate toxicity [4,5]. This process
of “drug repositioning” aims not to develop drugs de
novo, but associate existing therapeutics with new pheno-
types. Here, we attempted to reposition existing drugs to
treat common complex diseases using recently acquired
Genome-Wide Association Study (GWAS) data.
Complex diseases are genetically intricate, polygenic
and multifactorial [6]; and frequently arise as a conse-
quence of interaction between genes and the environ-
ment. Recently, GWAS have begun to unravel the
complicated genetic basis of complex diseases. Sheer
statistical power has allowed GWAS to successfully
identify some associations between Single Nucleotide
Polymorphisms (SNPs) and complex diseases [7].
Despite high investment, far fewer genes have been
identified than can account for the heritable component
of complex diseases, and the clinical benefit remains
limited to date [8]. A factor that contributes to the miss-
ing heritability is likely to be noisy genotype-phenotype
association signals [9]. Also, analysis of GWAS data
using highly stringent thresholds for statistical signifi-
cance, by testing multiple isolated SNPs, has limited the
scope of gene discovery based on existing data [10]. As
shown in Manhattan plots, GWAS data obviously con-
tain far more information than the most significant
peaks, and more work needs to be done extracting data
from slightly less significant peaks [9,11].
Currently available gene discovery platforms can
enhance candidate gene identification from GWAS data
[9]. Candidate gene prediction tools are designed to find
a needle in the genetic haystack. These tools are based
on the assumption that genes with similar or related
functions cause similar phenotypes [12]. Specific candi-
date gene prediction tools differ in the strategy adopted
for calculating similarity, and the databases utilized for
prediction [13,14]. Gentrepid is one of the many bioin-
formatic tools developed to help geneticists predict and
prioritize candidate genes [9,15]. The Gentrepid tool
and its knowledge base utilizes two independent meth-
ods: Common Pathway Scanning (CPS), a systems biol-
ogy approach; and Common Module Profiling (CMP), a
domain-based homology recognition approach, to priori-
tize candidate genes for human inherited disorders (see
Methods for details). Compared to other prediction
systems, Gentrepid is designed to make fewer, more
conservative predictions which do not extensively extra-
polate existing bioinformatic data i.e. it tends to be
more specific than other systems [15].
We have previously developed protocols to analyze
GWAS data using a multilocus approach which com-
bines bioinformatic and genetic data [9,16,17]. To
demonstrate the usefulness of these protocols, we reana-
lysed the well-studied Wellcome Trust Case-
Control Consortium (WTCCC) data for seven complex
diseases [9]. Using a series of increasingly less conservative
statistical thresholds, we attempted to discriminate the sig-
nal from the noise in the more statistically significant data
(p ≤ 10-5, p ≤ 10-4, p ≤ 10-3). By incorporating bioinfor-
matic data, we were able to predict 1,497 candidate genes
for the seven complex diseases studied; namely, Type 2
Diabetes (T2D), Bipolar Disorder (BD), Crohn’s Disease
(CD), Hypertension (HT), Type 1 Diabetes (T1D), Coron-
ary Artery Disease (CAD) and Rheumatoid Arthritis
(RA) [9].
Here, we extend this pipeline to identify potential novel
drug targets among the predicted candidate genes by
associating drug information extracted from publicly
available drug databases. The three databases sourced in
this study were DrugBank [18], the Pharmacogenomics
Knowledgebase (PharmGKB) [19] and the Therapeutic
Target Database (TTD) [20]. The feasibility of this
approach is again illustrated for the seven complex dis-
eases investigated by the WTCCC [11]. This study shows
that it is possible to identify therapeutics for treatment of
specific complex diseases from genetic loci via the Gen-
trepid candidate gene prediction tool. Thus, in combina-
tion with drug target information, candidate gene
prediction systems can be utilized as drug discovery tools
to identify therapeutics which may be repositioned as
novel treatments for complex diseases.
Methods
We implemented a computational workflow to enable
repositioning of drugs by using Gentrepid as a bioinfor-
matic candidate gene discovery platform, with drug data
sourced from online databases (Figure 1). The two data
sets integrated were:
1. A candidate gene data set obtained by integration of
genotype-phenotype data from the WTCCC GWAS study
on seven complex phenotypes [11], with bioinformatic
data on structural domains and systems biology: identify-
ing proteins that share common features, or participate in
the same complex or pathway [21];
2. A drug-gene target association data set obtained
from three drug databases namely TTD, DrugBank and
PharmGKB [18-20].
Candidate gene data set
In previous work, we predicted a total of 1,497 candidate
genes for seven complex diseases by careful reanalysis of
the WTCCC GWAS data [11] using the Gentrepid candi-
date gene prediction system [9].
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In the original analysis, a highly stringent significance
threshold (p ≤ 5x10-7) was used in an attempt to correct
for multiple testing [11]. This conservative statistical
approach, combined with the selection of the nearest-
neighboring gene to the significant SNP, resulted in
identification of only a small number of loci associated
with each phenotype, with modest cumulative heritabil-
ity [9] (Additional file 1, Table S1).
We specifically addressed these two issues in our reana-
lysis of this noisy data by - (a) Considering a series of four
thresholds of decreasing stringency, starting with the
highly significant threshold used in the original study, and
decreasing to weakly significant(WS - p ≤ 10-3). This
resulted in a series of four SNP sets containing up to 1064
SNPs being considered for each phenotype [9]. The num-
ber of loci and SNPs considered in the four data sets for
each phenotype is shown in Table S1 (Additional file 1).
(b) Creating six different search spaces around each
SNP-based locus, three of fixed-widths and three proxi-
mity-based, for analysis by our candidate gene predic-
tion system [9].
Thus, for each of the seven phenotypes, twenty-four
search spaces were constructed; using four SNP signifi-
cance thresholds to obtain the loci, and six gene selection
methods to construct the gene search spaces. In total,
168 search spaces ranging in size from 2 to 4,431 genes
(up to 10% of the genome) were analyzed [9].
Gentrepid uses two modules: Common Pathway Scan-
ning (CPS) and Common Module Profiling (CMP) to
make candidate gene predictions.
The CPS module is based on the assumption that com-
mon phenotypes are associated with proteins that partici-
pate in the same protein complex or biochemical pathway
[22]. Such systems biology methods are currently favored
in candidate gene prediction because of the attractiveness
of their basic thesis. Their weakness is the lack of coverage
of the underlying systems biology knowledge bases [21].
Many tools attempt to ameliorate the deficits of the
human systems biology knowledge base by extensive
extrapolation of data from other species. Examples
are GeneSeeker, ToppGene and Endeavour [13,23-25].
Gentrepid CPS uses only human data to reduce the num-
ber of predicted false positives i.e. it makes fewer predic-
tions which are more often correct compared to other
prediction systems [15].
The other module, CMP, is a novel sequence analysis
approach based on the principle that candidate genes have
similar functions to disease genes already determined for
the phenotype [26]. Gentrepid CMP differs from most
candidate gene prediction systems which describe func-
tional similarity via keywords, a procedure which also
lacks good coverage of the human genome [21]. In CMP,
sequences are parsed at the domain level, linking them
directly to function [21]. Although CMP’s performance
was disappointing in our original benchmark using a set of
nine oligogenic diseases with Mendelian inheritance [12],
it produced a surprising number of statistically significant
results when confronted with the GWAS data on seven
complex diseases [9]. This result was robust when com-
pared with simulations using random SNPs, and may arise
Figure 1 Workflow. The complete workflow designed to predict novel therapeutic targets and identify novel therapeutics. We used Gentrepid as
a platform for candidate gene prediction and DrugBank, TTD and PharmGKB as drug repositories.
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from an important underlying role for homologous genes
in complex diseases.
Drug-gene target data set
We compiled the drug-gene target data set from three
publicly available drug databases: DrugBank [18],
PharmGKB [19] and TTD [20]. Snapshots of these data-
bases were taken in June 2012.
DrugBank is a freely available online database that
combines detailed drug data and indication information
with comprehensive drug-target associations [18]. From
this database, we retrieved Drugbank IDs and drug
names (generic and brand) to represent drugs, and the
unique gene symbols to represent protein targets. We
extracted 6,711 drug entries active against 3,410 unique
drug targets from several species. We used the G-profiler
conversion tool to separate human drug targets repre-
sented by official HUGO gene symbols [27], yielding
2,022 human drug targets associated with 3,910 drugs.
The Pharmacogenomics Knowledgebase (PharmGKB)
is a drug knowledge base maintained by Stanford Uni-
versity, USA and funded by the US National Institute of
Health (NIH). PharmGKB captures information about
drugs, diseases/phenotypes and targeted genes [19].
From this database, we extracted the “drug-associated
genes” field along with “description” which contains the
disease information. This database contains around
3,097 drugs and 26,961 human genes, but not all these
genes are associated with drugs. We retrieved 382 drugs
for 566 human drug targets. For the PharmGKB data-
base, the number of drug targets exceeds the number of
drugs because some drugs target multiple genes.
The Therapeutic Target Database (TTD) is also a
freely available online drug database which integrates
drug data with therapeutic targets [20]. This database
contains 17,816 drugs (approved, clinical and experi-
mental) and 2,025 human and non-human (bacterial
and fungal) drug targets. It describes synonyms of 3,167
drug names. We extracted “Drug names” along with
“Disease” information, and “Uniprot accession numbers”
for targets. UniProt accession numbers were replaced
with official HUGO gene symbols using the G-profiler
conversion tool [27]. Finally, we extracted 2,960 drugs
for 544 unique human drug targets from TTD.
Mapping of candidate gene data set with the drug-gene
target data set
We mapped the list of 1,497 candidate genes with drug-
gene target association files obtained from the three
drug databases. The candidate genes for each disease
were mapped with the three drug-target association files
obtained from the three drug databases, and the results
retrieved.
Identification of novel therapeutics and therapeutic targets
In the next step, we identified novel therapeutic targets
and therapeutics for all seven diseases. If an associated
drug is not registered as a therapy for the phenotype of
interest, it is predicted as a novel therapeutic for the new
phenotype, directed towards the predicted candidate
gene target. The novel drugs may be suitable for reposi-
tioning towards treatment of the phenotype in question.
Validation of predicted therapeutic targets
The predicted therapeutic targets were validated using
two benchmarks. In the first benchmark, the ability of
the system to replicate known therapeutics de novo
from the genetic data was assessed. This benchmark
tests the system’s ability to retrieve existing knowledge;
however, this does not give any idea about the validity
of the novel predictions. To test the system’s ability for
knowledge discovery, we performed an additional
benchmark in which the validity of the candidate gene
predictions for the phenotype were assessed using text
mining of the literature.
In the first benchmark, genes present in the six search
spaces were classified as “candidates” or “non-candi-
dates”. We considered genes which are currently known
as drug targets for the phenotype of interest as “true
positives”. Targets with currently registered therapeutics
for the phenotype of interest which were not predicted
by Gentrepid but present in the search space were desig-
nated “false negatives”. Genes which were not predicted
and not targetable by drugs were “true negatives"; and,
for the purpose of this benchmark, predicted novel thera-
peutic targets were considered “false positives”. Receiver
Operation Characteristic (ROC) Curves were plotted in
GraphPad Prism 6 software considering six thresholds
obtained from the number of targets present in the six
search spaces for each phenotype. Linear, as well as non-
linear regression analysis, was performed (see section
Validation of predicted therapeutic targets in Results and
Discussion).
In the second benchmark, all Pubmed IDs of literature
related to Bipolar disorder, Type 1 diabetes, Type 2 dia-
betes, Crohn’s disease, Coronary artery disease, Rheuma-
toid arthritis and Hypertension were extracted from
Pubmed in Feb. 2013. For each target, we calculated the
number of citations using both the gene name and the
phenotype, by mapping the extracted Pubmed IDs to the
gene citation information from Entrez Gene (ftp://ftp.ncbi.
nih.gov/). Further, ROC curves were created in GraphPad
Prism 6 software considering four thresholds of at least
one, five, ten and fifteen citations. Non-linear regression
analysis was also performed to fit the ROC curves (see sec-
tion Validation of predicted therapeutic targets in Results
and Discussion).
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Results and Discussion
Comparison of drug databases
Firstly, we assessed coverage of the human genome by
the three drug databases both individually and in toto.
We extracted the following therapeutic drug-gene target
association data from the three databases:
1. 3,910 drugs against 2,022 human targets from
DrugBank [18];
2. 382 drugs against 566 human targets from
PharmGKB [19] and;
3. 2,960 drugs against 544 human targets from
TTD [20].
For more details about the content of these databases
see Methods.
The total number of unique targets from all the data-
bases was 2,494 genes, which is 8% of the entire human
genome (Figure 2). Previously, it was estimated that
3,000-5,000 genes are druggable (able to be modulated by
a small-molecule drug [28]) which is 10-17% of the entire
genome [29-32]. The gap between extracted targets from
the three drug databases (8%) and the estimated number
of druggable genes (10-17%) exists because many drug-
gable genes have not yet been mapped to a phenotype
and thus there has been no imperative to develop drugs
for these targets [33]. The targets searched in our study
cover 50-83% of the possible druggable genes mentioned
in previous studies [29-32].
We compared raw data such as drugs and drug targets
across the three drug databases to determine the redun-
dancy of the information in these databases. With respect
to drug targets, only 4% of human drug target entries were
common to all three databases (Figure 3). When the data-
bases were compared in a pairwise fashion, the proportion
of common targets ranged from 9-18%. Each of the data-
bases contains a significant amount of information that is
unique to that database. TTD has the fewest unique tar-
gets (129), while DrugBank and PharmGKB have 1,495
and 326 unique targets respectively (Figure 3).
Figure 2 Coverage of the human genome by targets annotated in the three drug databases. The Venn diagram shows that gene targets
annotated in drug databases comprise 8% of the entire human genome. It also describes the percentage of the genome covered by each
database individually and upon pairwise comparison.
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We also compared the number of drugs present in
three drug databases (Figure 4). Of the combined total of
9,991 unique drugs, DrugBank contributes 50% of the
unique drug compounds, while TTD and PharmGKB,
contribute 18% and 15% of the unique drug compounds
respectively (Figure 4). Using pairwise comparisons to
check redundancy of drugs between the databases, we
observed TTD and PharmGKB share 15-19% of their
listed drugs with DrugBank. Although there is significant
overlap among the three databases, the high number of
unique drugs in each database show the databases are
fairly complementary. In summary, all three drug data-
bases contain unique and valuable data and were thus all
used in the subsequent analysis.
Identification of therapeutic targets
We identified potential therapeutic targets for the seven
complex diseases from the Gentrepid predicted candi-
date genes generated by our reanalysis of the WTCCC
data. In total, Gentrepid predicted 1,497 candidate genes
for all seven diseases; comprising by phenotype: Type 2
Diabetes (291), Bipolar Disorder (212), Crohn’s Disease
(378), Hypertension (219), Type 1 Diabetes (358),
Coronary Artery Disease (264) and Rheumatoid Arthritis
(200) (Additional file 1 Table S1) [9]. We searched for
these candidate genes in the drug-gene target files
obtained from all three drug databases and found 452
potential therapeutic targets for the seven complex dis-
eases (Table 1). This illustrates that almost 30% of the
total number of predicted candidate genes by Gentrepid
are potential targets for therapeutic treatments using
currently available drugs (Figure 5). The disparity
between the 8% of the human genome that is targettable
(2,494 extracted targets - Figure 2) and the 30% of pre-
dicted candidate genes that are targettable (452 pre-
dicted targets - Figure 5) is interesting and should be
investigated further. The enrichment of druggable tar-
gets in the candidate gene set might be a selection
effect: either at the SNP level; or at the knowledgebase
level: it might suggest that we already know more about
disease genes than the genome in general. Alternatively,
it has been previously suggested that the genome can be
Figure 3 Comparison of human drug targets from three drug databases. Comparison of three drug databases to identify unique and
common human drug targets extracted from DrugBank, TTD and PharmGKB. DrugBank has the highest number of unique human targets
followed by PharmGKB and TTD.
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partitioned into “disease genes” and “non-disease genes”.
While such a Boolean distribution is likely to be overly
simplistic, a spectrum of levels of disease association
with specific gene subsets might explain this disparity.
To drill a little further into the data, we assessed the
therapeutic potential of each phenotype using currently
available repositioned drugs. We calculated an empirical
Targetability Index (TI), defined here as the ratio of the
number of predicted targets to the number of predicted
candidate genes for each phenotype (Table 1). The distri-
bution was bimodal with four phenotypes (CAD > RA >
CD > HT) being more targetable (TI = 0.35-0.39) than the
other three (T2D > T1D ~ BD) (TI = 0.27-0.29). A factor
which is likely to influence the targetability is our underly-
ing knowledge of the phenotype. If the molecular path-
ways involved have been previously characterized, there is
more likely to be drug-target information in the existing
drug databases, even if the phenotype has not previously
been associated with the molecular system. The low TIs
for BD (0.28) and the diabetes phenotypes (0.27-0.29)
likely arises from lack of knowledge of underlying path-
ways. More basic research in this area is required.
All three drug databases made significant contributions
to target identification, with the highest contribution from
DrugBank (400), followed by TTD (156) and PharmGKB
(61). DrugBank is a chemical as well as a clinical drug
Figure 4 Comparison of coverage of drugs in three drug databases. Comparison of drug coverage of three drug databases to identify
unique and common drugs. DrugBank has the highest number of unique drugs followed by TTD and PharmGKB.
Table 1 Repositioning potential and known therapeutic
targets by phenotype.
PH ≠ TT TI RN RTT NTT NV RN
T2D 84 0.29 5th 7 77 0.92 5th
T1D 97 0.27 6th 2 95 0.98 2nd
RA 77 0.38 2nd 6 71 0.92 5th
HT 78 0.35 4th 5 73 0.94 4th
BD 59 0.27 6th 1 58 0.98 2nd
CD 135 0.36 3rd 0 135 1.00 1st
CAD 102 0.39 1st 4 98 0.96 3rd
Abbreviations - PH - Phenotypes; ≠TT - Number of Therapeutic Targets; TI -
Targetability Index; NTT - Novel Therapeutic Targets; RTT - Replicated
Therapeutic Targets; NV - Novelty; RN - Rank; T2D - Type 2 Diabetes; BD -
Bipolar Disorder; CD - Crohn’s Disease; HT - Hypertension; T1D - Type 1
Diabetes; CAD - Coronary Artery Disease; RA - Rheumatoid Arthritis.
Description of therapeutic targets and novel therapeutic targets. Total 452
unique therapeutic targets and total 428 unique novel therapeutic targets
obtained for seven complex diseas
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database which contains broader coverage of drug targets
and broader depth of information compared to the chemi-
cal drug database TTD and the clinical drug database
PharmGKB. PharmGKB, being a clinical drug database,
has a lower coverage of drug-target associations, but
broader depth of information compared to TTD. To sum-
marize, the total coverage of the predicted targets from all
three databases was estimated to be 30% of the candidate
genes predicted by Gentrepid, with the maximum contri-
bution from DrugBank (Figure 5).
Discovery of novel therapeutic targets
For the seven diseases considered in our study, we per-
formed a binary classification of the 452 targets to dis-
tinguish therapeutic targets which were “rediscovered”
(or replicated) from novel potential therapeutic targets.
Novel genes are targeted by therapeutics registered for
other uses but not for the phenotype of interest. We
found 428 novel therapeutic targets accounting for
almost 94% of the targets identified in the previous sec-
tion. The remaining 24 targets have therapeutics which
either are approved, are in ongoing clinical trials, or
have been discontinued as therapeutics for the phenotype
of interest (Table 2). We considered these 24 known tar-
gets as “true positives” for the phenotypes of interest
in one of the benchmarks described below (see section
Validation of predicted therapeutic targets in Results and
discussion).
Figure 6 shows the number of novel therapeutic targets
obtained for each of the seven diseases, along with the
contribution from each drug database. The novelty of the
predicted targets for each disease was assessed by calcu-
lating the ratio of the number of novel therapeutic targets
to the number of therapeutic targets predicted for each
disease. The novelty ratio for all diseases was between
0.92 and 1.0 (Table 1). We observed the highest novelty
ratio for CD (1.0) and the lowest for RA (0.92). The high
ratio of novel targets for all phenotypes to predicted tar-
gets suggests repositioning could have a large impact on
clinical studies.
Identification of novel therapeutics
To identify novel drugs, we compared our phenotype of
interest (from the pool of seven diseases considered in our
Figure 5 Predicted therapeutic targets from three source databases. The Venn diagram represents the identified 30% of 1,497 candidates
are potential therapeutic targets for all the seven diseases. 17% of the targets were unique to one of the three drug databases (DrugBank), 1-2%
of targets were found in at least two databases (PharmGKB, TTD) and only 1.6% of targets are common to all the three drug databases.
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study) with indications associated with the drug. In total,
we retrieved 7,252 drugs associated with human drug tar-
gets from all three drug databases. We found 2,192 (30%
of the extracted drugs) unique drugs that target the 452
potential therapeutic targets.
We retrieved the maximum number of drugs from
DrugBank (1,618) and the remainder from TTD (735)
and PharmGKB (91). In order to identify the novel drugs
i.e. drugs not targeting our phenotype of interest, we fil-
tered the above list of 2,192 drugs to retrieve 2,130 novel
therapeutics. On a phenotype by phenotype basis, T1D
and CAD had the maximum number of novel predicted
therapeutics. Although CD had the highest number of
novel targets, it had comparatively few novel therapeutics
suggesting new drug development is needed for this phe-
notype. BD had the fewest therapeutics as expected based
on the small number of predicted therapeutic targets. We
found that the total percentage of drugs that may be
repositioned towards identified novel targets was around
29% of the total number of extracted drugs.
Table 2 shows the 24 replicated targets with examples of
replicated drugs found in our study. For example, the drug
“Aleglitazar” is in phase III clinical trial for the T2D target
PPARA, a predicted candidate gene for T2D. “Rosiglita-
zone” known to target PPARG as a therapeutic for diabetes
mellitus, has a potential use in the related phenotype T1D.
Examples of novel therapeutics for the seven phenotypes
are shown in Table 3. For example, “Pirenzepine”, which
acts upon the CHRM1 gene product, is approved as a
therapeutic drug for peptic ulcers. Our study predicts
CHRM1 is a predicted candidate gene and novel therapeu-
tic target for T2D, suggesting that the drug Pirenzepine
may be repositioned as a novel therapeutic for T2D.
Hence, the associated therapeutics for the novel therapeu-
tic targets may be repositioned against the phenotypes of
interest, accelerating the drug discovery process.
FDA-approved and clinical targets
Identification of therapeutic targets targeted by approved
and clinical trial drugs can help us to prioritize drugs for
Table 2 Predicted known therapeutics
PH Target *Drug name Status Action *Database
T1D PPARG Rosiglitazone Approved Agonist TTD
DGKA Vitamin E Approved Unknown DrugBank
T2D CTSD Insulin Regular Approved Unknown DrugBank
PPARA Aleglitazar Phase III Agonist TTD
NR3C1 ISIS-GCCR Preclinical Antisense TTD
TCF7L2 Repaglinide Unknown Unknown PharmGKB
PPARD Bezafibrate Approved Agonist DrugBank
RB1 Insulin, porcine Approved Unknown DrugBank
HSD11B1 INCB13739 Phase IIa Inhibitor TTD
RA TNF Infliximab Approved Inhibitor DrugBank
ITGA4 CDP323 Phase II Antagonist TTD
JAK2 INCB18424 Phase III Inhibitor TTD
IL15 AMG-714 Discontinued in phase I Inhibitor TTD
CCL2 MCP-1 Preclinical Inhibitor TTD
PRKCA Vitamin E Approved Unknown DrugBank
HT DRD1 Fenoldopam Approved Agonist TTD
AGTR1 Valsartan Approved Antagonist TTD
CNR1 AZD1175 Discontinued in phase I Antagonist TTD
AGT Benazepril Unknown Unknown PharmGKB
GUCY1A2 Isosorbide Mononitrate Approved Inducer DrugBank
BD SLC6A2 Imipramine Approved Inhibitor DrugBank
AGTR1 Valsartan Approved Antagonist DrugBank
CAD MYC AVI4126 Phase I/II Antisense TTD
PLG Urokinase Approved Activator DrugBank
NOS3 ACCLAIM Phase III Stimulator TTD
Abbreviations - PH - Phenotypes; T2D - Type 2 Diabetes; BD - Bipolar Disorder; HT - Hypertension; T1D - Type 1 Diabetes; CAD - Coronary Artery Disease; RA -
Rheumatoid Arthritis; TTD - Therapeutic Target Database; PharmGKB - Pharmacogenomics Knowledgebase.
Therapeutic targets with predicted known therapeutics for phenotypes of interest.
(* Drugs mentioned in the table are only examples as one target may have multiple drugs);
(* Drug databases in the table are only examples as one drug-target association may be present in more than one database).
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repositioning against phenotypes of interest. Both
approved and clinical targets are potential drug targets,
however, approved targets will undoubtedly be on the
priority list for further experimental studies. We classi-
fied the predicted targets as FDA-approved and clinical
targets for the seven complex diseases. An example
depicted in Figure 7 shows comparison between T2D tar-
gets from the TTD database and targets predicted by
Gentrepid for T2D. Of the 84 targets predicted for T2D
by Gentrepid (Table 1), 28 are listed in TTD (Figure 7).
Figure 6 Predicted therapeutic targets for each of the seven phenotypes. Abbreviations - T2D - Type 2 Diabetes; BD - Bipolar Disorder; CD
- Crohn’s Disease; HT - Hypertension; T1D - Type 1 Diabetes; CAD - Coronary Artery Disease; RA - Rheumatoid Arthritis. For each phenotype, the
contributions of each of the three drug databases are shown in primary colours on the left, and the set of total unique targets is shown in
green on the right. The cross-hatched portion of the bar shows targets replicated by the system which are already targeted by therapeutics for
that phenotype. The solid portions of the bars are novel predictions, which may potentially be utilized in repositioning.
Table 3 Novel therapeutics suitable for repositioning for the seven diseases
PH Target *Drug name Status Current Indication Action *Database
T1D RARA Alitretinoin Approved Kaposi’s sarcoma Agonist TTD
GSK3B Lithium Unknown Bipolar disorder Unknown PharmGKB
T2D CHRM1 Pirenzepine Approved Peptic ulcer disease Antagonist TTD
LPL Gemfibrozil Approved Hyperlipidemia Activator TTD
CAD FLT1 Sorafenib Launched Advanced renal cell carcinoma Inhibitor TTD
KDR Sunitinib Launched Advanced renal cell carcinoma Inhibitor TTD
BD ESR1 Trilostane Approved Cushing’s syndrome aModulator DrugBank
ABCC1 Methotrexate Unknown Psoriasis Unknown PharmGKB
HT TACR1 GSK1144814 Phase I Schizophrenia Antagonist TTD
NRP1 Palifermin Approved Oral mucositis Unknown DrugBank
CD CRHR1 CRF-1 antagonist Phase II completed Irritable bowel syndrome Antagonist TTD
INSR Insulin Detemir Approved Type I and II Diabetes Agonist DrugBank
RA HLA - DRB 1 Glatiramer Acetate Approved Multiple sclerosis Binder TTD
ACE Ramipril Approved Hypertension Inhibitor DrugBank
Abbreviations - PH - Phenotypes; T2D - Type 2 Diabetes; T1D - Type 1 Diabetes; CAD - Coronary Artery Disease; BD - Bipolar Disorder; HT - Hypertension; CD -
Crohn’s Disease; RA - Rheumatoid Arthritis; TTD - Therapeutic Target Database; PharmGKB - Pharmacogenomics Knowledgebase.
Examples of novel therapeutics suitable for repositioning towards cure of seven diseases. (* Drugs mentioned in the table are only examples as one target may
have multiple drugs); (* Drug databases in the table are only examples as one drug-target association may be present in more than one database); (a Allosteric
Modulator).
Grover et al. BMC Medical Genomics 2014, 7(Suppl 1):S8
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Comparing these 28 targets with the 32 targets indicated
for T2D in TTD, we found products of three genes
(HSD11B1, PPARA, NR3C1) are targeted by drugs cur-
rently in clinical trials for T2D. In addition, PPARA is
already targeted by FDA-approved drugs. Hence, we pre-
dicted 25 novel therapeutic targets from the TTD data-
base for T2D. In total for the seven diseases, we found
291 approved therapeutic targets and 95% of these as
novel approved targets. We also found 334 targets in
clinical trials and 96% of these being novel (Table 4). To
summarize, both approved and clinical novel targets are
associated with therapeutics, which may be repositioned
as novel treatments towards the cure of complex diseases.
Validation of predicted therapeutic targets
To assess the validity of targets predicted by Gentrepid for
each phenotype, we used two different benchmarks. In the
first benchmark, validity of the association of the gene
with the phenotype was based on whether they are desig-
nated as targets in the drug databases or not. This was
repeated for all six search spaces investigated for each phe-
notype. In the second benchmark, the validity of the asso-
ciation of the gene with the phenotype was assessed by the
existence or the absence of abstracts in the literature citing
both the gene name and the phenotype.
For the first benchmark, we performed a binary classifi-
cation of genes in the six search spaces as “candidates” or
“non-candidates”. As described in Table 5, targets with
therapeutic drugs for the phenotype of interest were
Figure 7 FDA-approved and clinical therapeutic targets. Abbreviation - T2D - Type 2 Diabetes; Comparison of Gentrepid predicted targets for
Type 2 diabetes targeted by FDA-approved and clinical trial drugs with targets obtained from the TTD database for Type 2 Diabetes. Three
predicted therapeutic targets (HSD11B1, PPARA, NR3C1) targeted by drugs currently in clinical trials for T2D. In addition, PPARA is also targeted by
FDA-approved drugs.
Table 4 Approved and clinical targets for seven complex
diseases
PH AT NAT CT NCT
T2D 45 41 65 62
T1D 57 55 73 72
HT 71 68 43 40
RA 55 53 59 54
CD 93 93 135 135
CAD 63 61 80 76
BD 37 36 44 44
Unique sum 291 277 334 318
Abbreviations - PH - Phenotypes; AT - Approved Targets; NAT - Novel Approved
Targets; CT - Clinical Targets; NCT - Novel Clinical Targets; T2D - Type 2 Diabetes;
T1D - Type 1 Diabetes; HT - Hypertension; RA - Rheumatoid Arthritis; CD - Crohn’s
Disease; CAD - Coronary Artery Disease; BD - Bipolar Disorder.
Predicted therapeutic targets targeted by FDA-approved drugs and drugs in
clinical trials.
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considered “true positives”. Targets with currently regis-
tered therapeutics for the phenotype of interest which
were not predicted by Gentrepid, but were present in the
search space as “false negatives”. Genes which were not
predicted and not targetable by drugs as “true negatives”
and Gentrepid-predicted novel therapeutic targets were
considered as “false positives” (Table 5). ROC curves were
plotted considering targets based on the six search spaces
from the weakly significant data set (Additional file 1,
Figure S1). Area Under Curve (AUC) values obtained
from these ROC curves were significantly greater than 0.5
(p < 0.05) (Additional file 1, Table S2). This suggests that
our predictions of novel therapeutic targets for all the
seven diseases are significant.
For the second benchmark, ROC curves for the seven
complex diseases were created by considering four thresh-
olds for targets cited by at least one, five, ten and fifteen
article citations as true positives and targets without any
citations or less than five, ten and fifteen citations as false
positives. Figure S2 (Additional file 1) contains all the
ROC curves and Table S2 (Additional file 1) contains the
AUC values. The AUC values for all the seven diseases
were significantly greater than from 0.5 (p < 0.05) meaning
that our results were significantly better than by chance.
This also suggests that our predictions of novel therapeu-
tic targets for all seven diseases are significant.
Significance of the work
The primary purpose of our work was to identify poten-
tial therapeutics and their targets by integrating publicly
available genetic, bioinformatic and drug data using the
Gentrepid candidate gene prediction platform. As the
method involves repositioning of currently available
drugs, it allows immediate translational opportunities
for drug testing [8]. Other bioinformatic tools have been
used to identify potential therapeutic targets for com-
plex diseases and other conditions. For example,
TARGET gene was used to identify and prioritize poten-
tial targets from hundreds of candidate genes for differ-
ent types of cancer [34]. Another study identified
potential drug targets for three neurological disorders -
Alzheimer’s disease, Parkinson’s disease and Schizo-
phrenia. This study involved the prediction of candidate
genes using the ToppGene and ToppNet prediction
systems [24,35]. The repositioning tools could be used
as an initial screening tool for potential drugs which
can be used for further evaluation [34]. It is important
to note that not all repositioning opportunities will
be successful as there are always some limitations
[36,37].
Conclusion
There is a need to develop new approaches for the iden-
tification of therapeutic targets to accelerate the process
of therapeutic drug discovery which has not kept pace
with discoveries in genetics. In this study, we integrated
detailed drug data with predicted candidate genes for
seven complex diseases. We found 29% of the predicted
candidate genes could serve as novel therapeutic targets
and 29% of the extracted drugs are potential novel ther-
apeutics for at least one of the seven complex diseases
considered in our study. We have utilized both FDA-
approved drugs and drugs in clinical trials. Further
investigation is required to verify the action of these
drugs. This study enables efficient identification of pos-
sible novel therapeutic targets and alternative indications
for existing therapeutics. Hence, these drugs may be
repositioned against seven phenotypes of interest,
quickly taking advantage of already done work in phar-
maceutics to translate ground-breaking results in genet-
ics to clinical treatments. Gentrepid, thus can be utilized
as a drug screening tool to save time and money spent
on the initial stages of drug discovery.
Additional material
Additional file 1: Gentrepid annotated SNPs, ROC curves and AUC
values for seven phenotypes. Table S1 - Gentrepid annotated SNPs
(clusters) for four data sets, WTCCC study associated loci (HS - p ≤ 5 x10-7 )
and Gentrepid predicted candidate genes per phenotype. Figure S1 - ROC
curves for seven diseases based on six thresholds obtained from targets
present in six search spaces in weakly significant data set. Table S2 AUC
values for ROC curves. Figure S2 ROC curves for seven diseases based on
four thresholds obtained using four cutoff of Pubmed citations (at least one,
five, ten and fifteen).
Table 5 Binary classification of therapeutic targets
PH Total genes in all
search spaces
Binary classification
T2D 4,292 TP = 7 FP = 77
FN = 9 TN = 4,199
T1D 5,339 TP = 2 FP = 95
FN = 9 TN = 5,233
HT 8,427 TP = 5 FP = 73
FN = 15 TN = 8,334
RA 4,970 TP = 6 FP = 71
FN = 9 TN = 4,884
BD 5,667 TP = 1 FP = 58
FN = 6 TN = 5,602
CD 5,644 TP = 0 FP = 135
FN = 0 TN = 5,509
CAD 4,715 TP = 4 FP = 98
FN = 8 TN = 4,605
Abbreviations - TP - True Positives; FP - False Positives; TN - True Negatives;
FN - False Negatives; TN - True Negatives; PH - Phenotypes; T2D - Type 2
Diabetes; T1D - Type 1 Diabetes; HT - Hypertension; RA - Rheumatoid Arthritis;
CD - Crohn’s Disease; CAD - Coronary Artery Disease; BD - Bipolar Disorder.
Binary classification of therapeutic targets considering targets present in six
search spaces from weakly significant data set.
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